SCHEMBL23611364

SCHEMBL23611364

CCOC(=O)CN(C(=O)OC(C)(C)C)c1cc(Cl)nc(C(F)(F)F)c1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.37
MAPK1 P28482 5/20 0.37
L3MBTL1 Q9Y468 4/20 0.37
P2RX3 P56373 1/20 0.37
HPGD P15428 6/20 0.36
KMT2A Q03164 4/20 0.36
HSD17B10 Q99714 4/20 0.36
TP53 P04637 3/20 0.36
NPSR1 Q6W5P4 3/20 0.36
TLR9 Q9NR96 3/20 0.36
BCL2A1 Q16548 2/20 0.36
MAPT P10636 2/20 0.36
RAB9A P51151 1/20 0.36
LMNA P02545 3/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
KDM4E B2RXH2 2/20 0.36
POLB P06746 1/20 0.36
ALOX15 P16050 1/20 0.36
HTT P42858 1/20 0.36
BID P55957 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30060460 1.00 ALDH1A1 (0.37) ALDH1A1MAPK1L3MBTL1P2RX3HPGD
SCHEMBL30060442 0.81 KCNQ4 (0.35) SOS1HDAC1HDAC8HDAC6
SCHEMBL23611521 0.79 ALDH1A1 (0.35) ALDH1A1MAPK1L3MBTL1P2RX3HPGD
SCHEMBL31168452 0.78 PAX8 (0.39) KMT2AKDM4EMEN1SOS1NFKB1
SCHEMBL5906809 0.78 P2RX3 (0.43) ALDH1A1L3MBTL1P2RX3KMT2ALMNA
SCHEMBL26260575 0.77 HDAC1 (0.37) SOS1NFKB1HDAC1HDAC8HDAC6
SCHEMBL30041593 0.77 HDAC1 (0.37) SOS1NFKB1HDAC1HDAC8HDAC6
SCHEMBL25213314 0.74 CYP3A4 (0.43) ALDH1A1P2RX3KMT2AMAPTSMN1; SMN2
SCHEMBL13247764 0.74 L3MBTL1 (0.37) ALDH1A1MAPK1L3MBTL1P2RX3KMT2A
SCHEMBL6213093 0.72 F2 (0.44) ALDH1A1MAPK1P2RX3HPGDHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4085057-B1 PYRIDINE AND PYRIMIDINE DERIVATIVES USEFUL AS PQSR INVERSE AGONISTS HELMHOLTZ ZENTRUM INFEKTIONSFORSCHUNG GMBH (DE) 2025-10-08 EP disclosed
US-20230106506-A1 NOVEL PqsR INVERSE AGONISTS Helmholtz-Zentrum für Infektionsforschung GmbH (DE) 2023-04-06 US disclosed
EP-4085057-A1 NOVEL PQSR INVERSE AGONISTS Helmholtz-Zentrum für Infektionsforschung GmbH (DE) 2022-11-09 EP disclosed
WO-2021136805-A1 NOVEL PqsR INVERSE AGONISTS Helmholtz-Zentrum für Infektionsforschung GmbH (DE) 2021-07-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230106506-A1 NOVEL PqsR INVERSE AGONISTS QRFPR, P2RY11, GPR55 ALDH1A1 4630/4885MAPK1 887/4885L3MBTL1 4496/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.